December 30, 2020
The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19. Investigators identified no safety concerns and no evidence of vaccine-associated enhanced respiratory disease (VAERD).
December 28, 2020
A NIH-supported Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers.
December 22, 2020
Preliminary results of a NIH Phase 3 clinical trial testing an investigative monoclonal antibody in hospitalized COVID-19 patients were published.
December 21, 2020
Reston ebolavirus should be considered a livestock pathogen with potential to affect other mammals, including people, according to NIH scientists.
December 18, 2020
The FDA issued an Emergency Use Authorization to Moderna, Inc. for its COVID-19 vaccine, which was co-developed with scientists at NIH NIAID and Moderna.
December 17, 2020
Two NIH-sponsored Phase 3 clinical trials are evaluating investigational monoclonal antibodies for treating people hospitalized with COVID-19.
NIH Observational Study of Coronavirus Infection and Multisystem Inflammatory Syndrome in Children Begins
December 16, 2020
A NIH study launched to evaluate the health outcomes of SARS-CoV-2 infection in children and to characterize the disease presentations and outcomes.
December 11, 2020
A NIAID supported study indicated possible ways to reduce time to recovery for people hospitalized with COVID-19.
December 1, 2020
Today on World AIDS Day, we reflect both on the remarkable progress that has been made against HIV as well as the considerable challenges that remain. We now have highly effective HIV treatment and prevention methods, and work is underway to address the remaining challenges in delivering these tools to the people who need them most, as well as to develop new interventions. The National Institutes of Health continues to advance rigorous, innovative research to prevent new HIV transmissions and improve the health of people with HIV worldwide.
November 30, 2020
NIAID announced the clinical investigators and institutions that will lead four NIH HIV clinical trials networks over the next seven years.
November 30, 2020
An experimental vaccine to prevent infection by Crimean-Congo hemorrhagic fever virus has protected cynomolgus macaques in a new NIH study.
November 25, 2020
NIAID announced that the Adaptive COVID-19 Treatment Trial has begun to enroll hospitalized adults with COVID-19 who require supplemental oxygen.
November 16, 2020
An independent review of NIH data suggests that the mRNA-1273 vaccine is safe and effective at preventing symptomatic COVID-19 in adults.
November 11, 2020
COVID-19 treatments for people with early infection are needed urgently, according to a JAMA Viewpoint article by NIAID Director Anthony S. Fauci, M.D., and colleagues. Treating people early in the course of infection with SARS-CoV-2, the virus that causes COVID-19, would speed their recovery, reduce the likelihood that they develop severe outcomes and reduce demand on the healthcare system, they write.
November 9, 2020
A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every eight weeks was safe and more effective than a daily oral PrEP regimen at preventing HIV acquisition among a group of cisgender women. The women, from southern and east Africa, are enrolled in a clinical trial sponsored by the National Institutes of Health.
October 26, 2020
The ACTIV-3 clinical trial evaluating the investigational monoclonal antibody LY-CoV555 in hospitalized patients with COVID-19 will not enroll more participants into this sub-study following a recommendation from the independent Data and Safety Monitoring Board (DSMB). The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
October 21, 2020
Results from a CDC and NIAID-sponsored clinical trial identify shorter-course treatment regimen for tuberculosis (TB).
October 13, 2020
NIAID launches a new study to identify promising COVID-19 treatments for larger clinical trials.
NIH Clinical Trial Testing Hyperimmune Intravenous Immunoglobulin Plus Remdesivir to Treat COVID-19 Begins
October 8, 2020
An NIH clinical trial began to test the hyperimmune intravenous immunoglobin plus remdesivir combination treatment regimen for COVID-19.
BULLETIN—NIAID Stops Enrollment of Severely Ill COVID-19 Participants in Clinical Trial of Investigational Treatments
September 29, 2020
The Adaptive COVID-19 Treatment Trial 3 (ACTT-3), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will no longer enroll hospitalized participants with severe COVID-19 requiring high-flow oxygen, and will not begin to enroll patients requiring non-invasive or invasive mechanical ventilation.
September 29, 2020
An investigational mRNA vaccine to prevent SARS-CoV-2 infection generates a strong immune response in a NIAID-supported Phase 1 trial.
September 24, 2020
New findings by scientists at the National Institutes of Health and their collaborators help explain why some people with COVID-19 develop severe disease. The findings also may provide the first molecular explanation for why more men than women die from COVID-19.
September 23, 2020
A fourth Phase 3 NIH clinical trial evaluating an investigational vaccine for coronavirus disease 2019 (COVID-19) has begun enrolling adult volunteers.
September 9, 2020
An experimental treatment for eczema safely reduced disease severity and increased quality of life for children as young as 3 years old, NIH study shows.
August 31, 2020
A NIAID-supported Phase 3 clinical trial evaluating an investigational COVID-19 vaccine called AZD1222 will enroll around 30,000 adult volunteers.